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HK1 variant, glycated hemoglobin and anemia 
A genetic variant in HK1 is associated with pro-anemic state and HbA1c but 
not other glycemic control related traits 
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Objective: HbA1c is widely considered as a gold standard for monitoring effective blood glucose 
levels. Recently, a genome-wide association study reported an association between HbA1c and 
rs7072268 within HK1 (encoding Hexokinase 1) which catalyzes the first step of glycolysis. 
HK1 deficiency in red blood cells (RBC) causes severe nonspherocytic hemolytic anemia in both 
humans and mice.  
 
Research Design and Methods: The contribution of rs7072268 to HbA1c and the RBC-related 
traits was assessed in 6,953 non-diabetic (ND) European participants. We additionally analyzed 
the association with hematologic traits in 5,229 ND European individuals (where HbA1c was not 
measured) and 1,924 diabetic patients. Other glucose control related markers than HbA1c were 
analyzed in 18,694 ND European individuals. A type 2 diabetes case-control study included 
7,447 French diabetic patients.  
 
Results:  Our study confirms a strong association between rs7072268-T allele and increased 
HbA1c (β=0.029%HbA1c,P=2.22×10
-7). Surprisingly, despite an adequate study power, rs7072268 
showed no association with any other marker of glucose control (fasting- and 2h-post-OGTT-
related parameters;N=18,694). In contrast, rs7072268-T allele decreases hemoglobin levels 
(N=13,416;β=-0.054g/dl,P=3.74×10
-6) and hematocrit (N=11,492;β=-0.13%Hematocrit,P=2.26×10
-
4), suggesting a pro-anemic effect. The T-allele also increases risk for anemia 
(Ncases=846,OR=1.13,P=0.018). 
 
Conclusions:  HK1 variation although strongly associated with HbA1c does not seem to be 
involved in blood glucose control. Since HK1 rs7072268 is associated with reduced hemoglobin 
levels and favors anemia, we propose that HK1 may influence HbA1c levels through its anemic 
effect and/or its effect on glucose metabolism in RBC. These findings may have implications for 
T2D diagnosis and clinical management, as anemia is a frequent complication of the diabetic 
state. HK1 variant, glycated hemoglobin and anemia 
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ype 2 diabetes (T2D) is a major source 
of early excess morbidity and mortality 
that results from the lack of adequate 
control of blood glucose in most diabetic 
patients (1). In the absence of widely 
available continuous glucose monitoring, the 
glycated hemoglobin (HbA1c) assay has 
become the most popular index to evaluate 
the efficiency of T2D treatments on long-term 
blood glucose control (2; 3). HbA1c which is 
formed through the non-enzymatic attachment 
of glucose to the N-terminal of the β chain of 
hemoglobin is indeed commonly considered 
as a surrogate marker of mean blood glucose 
concentration over the previous 8–12 weeks 
(i.e. 120 days lifespan of erythrocytes) (4). 
Furthermore, the HbA1c assay is often used 
for confirming T2D diagnosis when fasting 
plasma glucose (FPG) is in the pre-diabetic 
range (6.1 mM ≤ FPG < 7.0 mM that define 
normal glycemia and overt diabetes (2)), as 
post prandial or post glucose load 
measurements of blood glucose are difficult 
to widely apply in clinical practice. However, 
the HbA1c measurement displays well known 
caveats such as genetically inherited 
hemoglobin defects or red blood cell (RBC) 
life span heterogeneity in hematologically 
normal people that would oblige the use of 
more complex measurement of glycated 
serum proteins or fructosamine as a surrogate 
of blood glucose levels (5; 6). 
So far, several genome-wide 
association studies (GWAS) have identified 
22 genes or loci increasing the risk for T2D 
and/or modulating FPG levels (7-19). 
Recently, Paré et al. reported a single 
nucleotide polymorphism (SNP) rs7072268 at 
the Hexokinase 1 (HK1) locus (chr10q22) that 
strongly associates with increased HbA1c in a 
non-diabetic population (20). The four 
isozymes of the hexokinase family (named 
HK1, HK2, HK3 and glucokinase) contribute 
to commit glucose to the glycolytic pathway. 
The predominant HK1 isozyme is expressed 
in the vast majority of cells and tissues, 
including cells that are strictly dependent on 
glucose uptake for their metabolic needs (21). 
Importantly, while most tissues express more 
than one HK isozyme, RBC glucose 
metabolism only depends on HK1 activity 
(22). In humans, mutations including non-
synonymous substitutions in the active site of 
HK1 and intragenic deletions have been 
shown to cause HK1 enzymatic deficiency 
associated with autosomal recessive severe 
nonspherocytic hemolytic anemia (21; 23-25). 
A similar phenotype has been described in the 
Downeast Anemia (dea) mice displaying HK1 
deficiency (22).  
Based on these observations, we 
postulated that HK1 genetic variation may 
modulate the maintenance of the RBC pool 
and thus indirectly alter HbA1c measurements 
independently of the ambient blood glucose 
concentration. We evaluated this hypothesis 
by assessing the impact of HK1 rs7072268 on 
HbA1c, other glucose control-related traits, 
T2D risk and RBC-related parameters in 
several prospective and case/control European 
cohorts. Our data suggest that HK1 variation 
through its anemic effect impairs HbA1c 
assays, which may have important clinical 
implications for both T2D diagnosis and 
management, as anemia is commonly 
associated with diabetes. 
  
RESEARCH DESIGN AND METHODS 
Study Participants:  Clinical 
characteristics and data available on the 
studied populations are reported in Table 1. 
The study protocol was approved by the local 
ethics committee and participants from all 
studies described here (and parents of 
children) signed an informed consent form.  
Genotyping of rs7072268 was 
performed in several cohorts:  
D.E.S.I.R.  The Data from the 
Epidemiological Study on the Insulin 
Resistance Syndrome (D.E.S.I.R.) cohort is a 
longitudinal French general population, 
described elsewhere (10; 26). We analyzed 
T HK1 variant, glycated hemoglobin and anemia 
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4,590 non-diabetic D.E.S.I.R. participants 
successfully genotyped for rs7072268; of 
whom 3,795 were examined during the entire 
9-year study.  
Swiss Obese Adults. The Swiss cohort 
study of obese adults was fully described 
elsewhere (27). All of them were recruited for 
obesity surgery. We analyzed 2,363 non-
diabetic participants successfully genotyped 
for rs7072268. 
NFBC1986.  The Northern Finland 
1986 Birth Cohort (NFBC1986) is a 
prospective 1-year birth cohort including all 
Finnish Caucasian mothers with children 
whose expected date of birth fell between July 
1st 1985 and June 30th 1986 in the two 
northernmost provinces of Finland (28). 
Clinical examination at 15-16 years follow-up 
was conducted between August 2001 and 
June 2002. We analyzed 5,287 non-diabetic 
participants in the NFBC1986 cohort 
successfully genotyped for rs7072268.  
Haguenau. The Haguenau 
community-based cohort of young adults 
investigates long-term consequences of being 
born small for gestational age and was fully 
described elsewhere (29). Briefly, subjects 
born between 1971 and 1985 were identified 
from a population-based registry of Haguenau 
(France). Non European ancestry subjects are 
estimated to be less than 0.1% of the general 
population (29). At a mean age of 22 years, 
participants under overnight fasting 
conditions underwent a medical examination 
to assess anthropometric and clinical 
parameters. We analyzed 1,455 non-diabetic 
participants successfully genotyped for 
rs7072268.  
Obesity French Pedigrees. French 
children and adults with European ancestry 
from obesity families were recruited at the 
CNRS-UMR8090 unit (Lille, France) through 
an ongoing national media campaign (30). We 
analyzed 5,261 non-diabetic participants 
successfully genotyped for rs7072268.  
French type 2 diabetes case-control 
study.  We analysed 7,447 unrelated French 
individuals with T2D ascertained from the 
French T2D family and Obesity family 
studies, collected by the CNRS-UMR8090 
unit; from the Endocrinology-Diabetology 
Department of the Corbeil-Essonnes Hospital 
(7) and from the Diabhycar/Diab2-
Néphrogène/Surdiagène study (31). We used 
5,380 unrelated normoglycemic participants 
(age at exam > 40 years) as controls 
ascertained from the D.E.S.I.R. cohort, the 
SU.VI.MAX study fully described elsewhere 
(32), and the French T2D family and Obesity 
family studies recruited by the CNRS-
UMR8090 unit.  
For each population, glycemic status 
was defined according to 1997 American 
Diabetes Association criteria (2): normal 
glucose, defined as fasting glucose < 6.1 
mmol/l without hypoglycemic treatment; and 
T2D, defined as FPG ≥ 7.0 mmol/l and/or 
treatment with anti-diabetic agents. For the 
Corbeil study, ‘overt nephropathy’ was 
defined as: microalbuminuria levels ≥ 30 
mg/24h or microalbuminuria levels ≥ 20 mg/l 
in two out of three urinary takings.  
Genotyping:  Genotyping of SNP 
rs7072268 was performed using a TaqMan™ 
assay according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, 
CA, USA; AB assay ID C-30005592-10). 
Allelic discrimination was performed by 
capillary electrophoresis analysis using an 
Applied Biosystems 3730xl DNA Analyser 
and GeneMapper 3.7 software. Genotype 
success rate was at least 98% and no 
deviation (p > 0.05) from Hardy-Weinberg 
equilibrium was observed in any of the 
examined populations.  
Genotyping of MTNR1B-rs10830963, 
GCK-rs1799884, G6PC2-rs560887 and 
SLC30A8-rs13266634 in the D.E.S.I.R. study 
had previously been reported (10; 19; 33; 34). 
Statistical analyses: We analyzed the 
effect of SNP rs7072268 on quantitative traits HK1 variant, glycated hemoglobin and anemia 
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using linear regression models under an 
additive model adjusted for age, gender and 
BMI. To take into account familial 
relationships within the French obesity 
pedigrees, we tested the association between 
rs7072268 and glucose homeostasis-related 
traits using Gaussian models of generalized 
estimated equations (GEE) performed with 
STATA software. The estimates of the effect 
of rs7072268 on quantitative traits and their 
standard errors for each separate population 
were combined in the meta-analyses using the 
weighted inverse normal method. The overall 
effect and its confidence interval were 
estimated using the inverse variance method 
implemented in ‘meta.summaries’ function of 
R RMETA package. The effect of rs7072268 
on diabetic status was assessed using a 
logistic regression model adjusted for age, 
gender and BMI. In the D.E.S.I.R. 
participants, the effect of the rs7072268 
genotype on quantitative traits was assessed 
in non-diabetic individuals at baseline and 
using repeated measures at 3-, 6-, and 9-year 
follow-up visits. We used mixed models for 
analyses of repeated measures adjusted for 
age, gender and BMI. Using the QUANTO 
software, we estimated what significant 
effects of rs7072268 on glucose homeostasis 
related parameters we could expect in the 
related meta-analyses, with a detection power 
of 80%. Given the analyzed sample sizes, 
small effects of HK1 rs7072268 (estimated at 
β  ≤ |0.1|) on glucose homeostasis related 
parameters can be detected with a power of 
80%. 
All statistical analyses were performed 
with R (version 2.6.1), SPSS (version 14.0 for 
Windows), QUANTO (version 1.2) and 
STATA software (version 5.0). 
Indices calculation: The homeostasis 
model of pancreatic beta cell function 
(HOMA-B) was calculated as HOMA-B = 
(20 × ‘fasting serum insulin’)/(‘fasting plasma 
glucose’ – 3.5) where ‘fasting serum insulin’ 
is in mU/l and ‘fasting plasma glucose’ is in 
mmol/l (35).  
The homeostasis model of insulin 
resistance (HOMA-IR) was calculated as 
HOMA-IR = (‘fasting plasma glucose’ × 
‘fasting serum insulin’) / 22.5 where ‘fasting 
serum insulin’ is in pmol/l and ‘fasting 
plasma glucose’ is in mmol/l (35). 
The insulinogenic index, the insulin 
sensitivity index (ISI) and the disposition 
index (DI) were calculated from the oral 
glucose tolerance test (OGTT) according to 
the formulas: 
   Insulinogenic index = (‘serum insulin 
at 30 minutes’ – ‘fasting serum insulin’) / 
‘plasma glucose at 30 minutes’ where serum 
insulin is in pmol/l and plasma glucose is in 
mmol/l (36). 
ISI = 10,000 / √(‘fasting plasma 
glucose’ × ‘fasting serum insulin’ × mean 
OGTTglucose × mean OGTTinsulin) where serum 
insulin is in mU/l and plasma glucose is in 
mmol/l (37). 
DI = ISI × 100 ×  ‘serum insulin at 30 
minutes’ / [‘plasma glucose at 30 minutes’ ×  
(‘plasma glucose at 30 minutes’ – 3.89)] 
where serum insulin is in mU/l and plasma 
glucose is in mmol/l (38). 
ISI and DI were only calculated in the 
French obese pedigrees as measurements of 
serum insulin and plasma glucose were 
available at 0, 30, 60, 90 and 120 minutes 
after glucose load. In the Haguenau study, 
measurements of serum insulin and plasma 
glucose were only available at 0, 30, and 120 
minutes after glucose load. 
 
RESULTS 
SNP rs7072268 strongly associates 
with increased HbA1c level in non-diabetic 
individuals.  We first genotyped SNP 
rs7072268 in 4,590 middle-aged non-diabetic 
individuals from the French D.E.S.I.R. 
population (mean age 47 years) and in 2,363 
Swiss non-diabetic obese adults (mean age 41 
years) (see clinical characteristics in Table 1). HK1 variant, glycated hemoglobin and anemia 
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Applying an additive genetic model adjusted 
for age, gender and BMI, the rs7072268-T 
allele showed a consistent association with 
increased HbA1c in the D.E.S.I.R. study at 
baseline and over the 9-year follow-up (β = 
0.023 %HbA1c [0.016;0.031]95%CI, P = 1.76 × 
10
-3 and β = 0.022 %HbA1c [0.016;0.029]95%CI, 
P = 3.93 × 10
-4, respectively; Table 2) and in 
the Swiss obese adults sample set (β = 0.046 
%HbA1c  [0.032;0.060]95%CI,  P = 9.46 × 10
-4; 
Table 2). These results were unchanged when 
the additive genetic model was adjusted for 
age and gender only (data not shown). When 
we also included FPG level in the linear 
regression model, the significance of the 
effect on HbA1c was stronger in both studies 
as well as in a meta-analysis of the D.E.S.I.R. 
baseline data and the Swiss obese samples (N 
= 6,953; β = 0.029 %HbA1c [0.018;0.040]95%CI, 
combined P = 2.22 × 10
-7; Table 2).  
SNP rs7072268 does not associate 
with any other markers of glucose control 
in non-diabetic individuals. We then 
assessed the impact of the rs7072268-T allele 
on glucose homeostasis-related traits in 
D.E.S.I.R. and the Swiss samples. Applying 
an additive genetic model adjusted for age, 
gender and BMI, we did not find significant 
associations between rs7072268 and any 
glucose-related traits including fasting 
glucose, fasting insulin and the homeostasis 
models of pancreatic beta cell function 
(HOMA-B) and insulin resistance (HOMA-
IR) (Table 3).  
In order to support further these 
paradoxical findings, we tested the effect of 
rs7072268 on the same fasting traits in 12,003 
additional non-diabetic individuals 
ascertained from the NFBC1986 study (age at 
the examination 16 years), from the French 
Haguenau cohort (mean age 22 years) and 
from French obesity pedigrees including both 
children and adults (mean age of 11 and 46 
years, respectively) (see clinical 
characteristics in Table 1). HbA1c levels were 
not measured in these sample sets. Applying 
an identically adjusted additive genetic 
model, we did not find significant 
associations with any of these traits analyzed 
in each cohort nor in the overall combined 
meta-analysis (Table 3). Furthermore, 
analyses of glucose and insulin levels after 
oral glucose load in 1,440 individuals from 
Haguenau; in 1,055 children and in 2,294 
adults from the French obesity pedigrees did 
not show any significant associations (Table 
4).  
SNP rs7072268 associates with 
RBC-related parameters and anemia in 
non-diabetic individuals.  Since our results 
so far suggested that the effect of rs7072268 
on HbA1c was not due to differences in 
glycemic status, we assessed the impact of 
rs7072268 on RBC-related parameters 
available in D.E.S.I.R. and the Swiss obese 
adults sample set; and also in 5,229 
participants from the NFBC1986 study 
(where RBC-related traits but not HbA1c 
were measured). Applying an additive genetic 
model adjusted for age, gender and BMI, our 
combined analysis demonstrated an 
association between the rs7072268-T allele 
and decreased hematocrit (N = 11,492; β = -
0.13 %hematocrit [-0.20;-0.06]95%CI, combined P 
= 2.26 × 10
-4; Table 5) and decreased 
hemoglobin levels (β = -0.044 g/dl [-0.071;-
0.017]95%CI, combined P = 1.43 × 10
-3; Table 
5). Combined case-control studies for anemia 
(stringently defined by hemoglobin ≤ 12 g/dl 
for females and ≤ 13 g/dl for men; Ncases = 
669) from the same cohorts supported further 
the anemic effect of the rs7072268-T allele 
(OR = 1.13 [1.01;1.27]95%CI; combined P = 
0.032). We next studied the effects of 
variation at rs7072268 on mean corpuscular 
hemoglobin (MCH) and mean corpuscular 
volume (MCV) indices: since the P values for 
heterogenity in effects on both traits were 
lower than 0.05, our analysis was performed 
in each cohort in isolation. In Swiss obese 
adults, the rs7072268-T allele associates with 
both decreased MCH and MCV parameters (β HK1 variant, glycated hemoglobin and anemia 
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= -0.21 pg/cell [-0.28;-0.14]95%CI, P = 2.16 × 
10
-3 and β = -0.56 ×10
-15l/cell [-0.72;-
0.38]95%CI, P = 1.29 × 10
-3 respectively; Table 
5), suggesting a microspherocytocytic anemic 
state. In the D.E.S.I.R. participants, the RBC 
count also showed a negative association with 
the rs7072268-T allele both at baseline (β = -
0.018 ×10
12/l [-0.025;-0.011]95%CI, P = 8.01 × 
10
-3; Table 5) and over the 9-year follow-up 
(β = -0.020 ×10
12/l [-0.027;-0.014]95%CI, P = 
9.63 × 10
-4 respectively; Table 5).   
Effect of SNP rs7072268 on RBC-
related parameters in T2D individuals. The 
rs7072268-T allele is also associated with 
decreased hemoglobin level in 1,924 French 
T2D subjects from the Corbeil Hospital 
cohort where this parameter was measured (β 
= -0.13 g/dl [-0.16;-0.09]95%CI, P = 7.66 × 10
-
4; Table 5). When the presence of overt 
nephropathy, the microalbuminuria level or 
the albumin-to-creatinine ratio were 
introduced in the linear regression model, this 
association remained significant (P < 1.5 × 
10
-3) suggesting that the effect of HK1 on 
RBC is independent of diabetes-linked kidney 
disease. We also identified in T2D subjects a 
trend for association between the rs7072268-
T allele and decreased MCV (Table 5).  
Combined meta-analysis of SNP 
rs7072268 on RBC-related parameters. In a 
combined meta-analysis including non-
diabetic and T2D participants, the rs7072268-
T allele strongly associates with decreased 
hemoglobin levels (N  = 13,416; β = -0.054 
g/dl [-0.076;-0.031]95%CI, combined P = 3.74 
× 10
-6; Table 5) and trend for an increased 
risk for clinical anemia (Ncases = 836; OR = 
1.13 [1.02;1.25]95%CI, combined P = 0.018) is 
supported further. 
Impact of SNP rs7072268 on T2D 
risk.  We then assessed the contribution of 
rs7072268 to T2D risk in 7,447 T2D French 
individuals and 5,380 unrelated 
normoglycemic French controls (age at exam 
≥ 40 years old). The T2D case-control 
analysis only displayed a nominal association 
between the rs7072268-T allele and increased 
risk of T2D (OR = 1.07 [1.00;1.14]95%CI, P = 
0.045; Table 6). These findings were not 
supported by GWAS meta-analyses carried 
out by the DIAGRAM+ consortium including 
8,130 T2D and 38,987 controls European 
participants (OR = 0.98 [0.94;1.02]95%CI, P = 
0.40) (unpublished data).   Therefore, weak 
HK1 rs7072268 effect found in our samples 
on increased T2D risk is not supported further 
in other European populations.  
Impact of the five established 
genetic determinants of HbA1c on HbA1c 
levels, fasting plasma glucose and RBC-
related parameters in D.E.S.I.R.  We then 
analysed the contribution of four previously 
reported genetic determinants of HbA1c (i.e. 
MTNR1B-rs10830963 (9; 34), GCK-
rs1799884 (20), G6PC2-rs560887 (20) and 
SLC30A8-rs13266634 (20)) on HbA1c levels 
in the D.E.S.I.R. cohort. We confirmed the 
contribution of these SNPs to HbA1c levels in 
~4,500 non-diabetic individuals from the 
D.E.S.I.R. study at baseline, except for the 
SLC30A8-rs13266634 that displayed only a 
trend for association with HbA1c levels 
(PMTNR1B = 2.25 × 10
-4, PGCK = 1.32 × 10
-4, 
PG6PC2 = 2.31 × 10
-6 and PSLC30A8 = 0.063; 
Table 7). Analysis of HK1-rs7072263 
combined with the four other SNPs 
demonstrated a significant additive effect on 
HbA1c levels (βper-allele = 0.032 %HbA1c, P = 
1.49×10
-15; Figure 1). Individuals carrying 
seven or more ‘high HbA1c’ alleles (N = 415; 
~11% of the European population) show a 
mean of 0.17 % increase in HbA1c as 
compared with individuals carrying fewer 
than two ‘high HbA1c’ alleles (N = 219) 
(Figure 1). 
We then assessed the effect of 
MTNR1B-rs10830963,  GCK-rs1799884, 
G6PC2-rs560887 and SLC30A8-rs13266634 
on FPG levels and RBC-related parameters 
including RBC count, hemoglobin and 
hematocrit levels. As previously reported (9; 
10; 19; 33), the four SNPs are strongly HK1 variant, glycated hemoglobin and anemia 
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associated with FPG levels (Table 7). SNPs 
GCK-rs1799884, G6PC2-rs560887 and 
SLC30A8-rs13266634 are not associated with 
RBC-related parameters (Table 7). In 
contrast, the MTNR1B-rs10830963-T allele 
associates with decreased RBC count, 
hemoglobin and hematocrit levels (β = -0.017 
×10
12/l [-0.025;-0.001]95%CI, P = 0.022; β = -
0.055 g/dl [-0.076;-0.033]95%CI, P = 0.011 and 
β = -0.19 %hematocrit [-0.25;-0.12]95%CI,  P = 
4.13 × 10
-3, respectively; Table 7). 
 
DISCUSSION 
Our data unambiguously demonstrate 
that HK1 rs7072268 strongly associates with 
increased HbA1c levels in European general 
populations, as reported by Paré et al. (20). In 
contrast, we failed to find any further 
association with other quantitative metabolic 
traits commonly used to monitor glucose 
control. In addition, it is unlikely that HK1 
rs7072268 significantly increases risk for 
T2D. Our data suggest that the effect of HK1 
variation on HbA1c levels may be due to a 
molecular mechanism involving RBC 
function, rather than related to impaired blood 
glucose homeostasis. In this regard, we found 
that the HK1 rs7072268-T allele increasing 
HbA1c is strongly associated with both 
reduced hemoglobin and hematocrit levels 
(the Spearman correlation between hematocrit 
and hemoglobin levels in non-diabetic people 
from D.E.S.I.R. is: r² = 0.94, P < 0.0001). In 
addition, the rs7072268-T allele contributes to 
increase the risk of clinical anemia. However, 
this result has to be confirmed in large scale 
and more powered case/control studies. To 
support our findings, dea mice having HK1 
deficiency also display lower RBC count, 
hemoglobin and hematocrit levels (22). 
Indeed, these mice show a severe anemia with 
extensive tissue iron deposition and marked 
reticulocytosis that results from significant 
intravascular hemolysis (22). About 20 
patients with nonspherocytic hemolytic 
anemia due to HK1 deficiency have been 
described so far (21), but there is no 
information available about their HbA1c 
levels. SNP rs7072268 is located in the first 
intron of the HK1 isoform HK1-R specifically 
expressed in RBC and is in intermediate 
linkage disequilibrium with a common non-
synonymous coding SNP rs1133189 
(according to the HapMap CEU population: r² 
= 0.58). Although we have no obvious 
information about the truly causative common 
SNPs in the HK1 locus associated with 
anemia (that might be obtained from fine 
mapping studies), we speculate they may 
impair HK1 expression and/or the maturation 
of this hexokinase enzymatic isoform in 
reticulocytes and in mature RBC, as known in 
monogenic HK1 deficiency (21; 23).  
In RBC, the oxygen affinity of 
hemoglobin is strongly regulated by 2,3-
biphosphoglycerate (2,3-DPG) produced by a 
bypass in glycolysis (21). Increasing 2,3-DPG 
levels cause a decreased oxygen affinity and 
thus improve the transfer of oxygen to tissues 
and ameliorate the anemic state. HK1 
deficiency contributes to decrease 2,3-DPG 
levels and thus annuls its beneficial effect 
(21). HK1 is also known to bind in 
mitochondria to the voltage-dependent anion 
channels (VDACs), known as mitochondrial 
porins (39). Mitochondrial associated 
hexokinase activity has been shown to protect 
cells from entering apoptosis via the blockade 
of the interaction of the pro-apoptotic BAX 
with the VDAC (40-42). We speculate that 
HK1 variation may impair the HK1 anti-
apoptotic effect in reticulocytes (i.e. the 
precursors of RBC), as well as in kidney and 
brain where HK1 is expressed (21; 43). It may 
have deleterious effects on maturation of 
RBC as well as on erythropoiesis via 
decreased synthesis of kidney and brain 
erythropoietin (Epo).                 
The mechanism by which HK1 related 
anemia increases HbA1c levels is unknown. 
Using a conditional regression model, we 
failed to clearly show that the HK1 effect on HK1 variant, glycated hemoglobin and anemia 
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HbA1c was affected by adjustment for the 
hemoglobin or hematocrit levels (see Table 
A1 in the online appendix  at 
http://diabetes.diabetesjournals.org). This may 
suggest that the hemoglobin or hematocrit 
levels would explain a small variance of 
HbA1c. But, larger studies will be needful to 
confirm these findings. A higher turnover of 
the RBC pool should diminish protein 
glycation due to the reduced hemoglobin half 
life (5). Alternatively, we speculate that the 
enhanced accumulation of unprocessed 
glucose resulting from the HK1 deficiency 
may favor hemoglobin glycation within RBC, 
which in turn may increase the RBC death 
rate via their impaired deformability (44). 
Importantly, anemia due to iron deficiency 
often seen in late pregnancy, also causes 
increased HbA1c levels (45) and HbA1c 
levels significantly decreases after iron or 
vitamin B12 treatment in patients with iron or 
vitamin B12 deficiency anemia, respectively 
(46; 47). Therefore, different anemia inducing 
mechanisms increase HbA1c levels.   
Other genes associated with RBC-
related parameters may also interfere with the 
glycation of hemoglobin. In this regard, our 
present data suggest that genetic variation in 
MTNR1B (encoding melatonin receptor 2), 
which strongly influences both HbA1c and 
fasting glucose (9), also associates with 
decreased RBC-count, hemoglobin and 
hematocrit levels. Melatonin is a 
neurohormone mainly involved in the 
regulation of circadian rhythms. Recently, 
Bozek et al. provided evidence of a circadian 
oscillation of Epo gene expression in the 
kidney (48), a tissue that strongly expresses 
MTNR1B in rat (49). In contrast, three other 
genetic determinants of HbA1c (i.e.  GCK, 
G6PC2 and SLC30A8) modulate fasting 
glucose but do not influence hematologic 
parameters measured in our cohorts. 
Altogether, HbA1c levels seem to be largely 
genetically determined (Figure 1) possibly via 
the modulation of blood glucose and/or 
hematologic parameters.       
As both the American Diabetes 
Association and the European Association for 
the Study of Diabetes have proposed to use 
HbA1c as a criterion for T2D diagnosis (an 
individual with HbA1c lower than 6 % is 
considered as non-diabetic), both genetic and 
environmental factors (including iron and 
vitamin B12) interacting with RBC function 
and survival, have to be taken into 
consideration to better interpret HbA1c levels 
in the general population. Furthermore, 
diabetes by itself is a known cause for anemia 
through a range of deleterious mechanisms 
(44), and it would be important to better 
determine the impact of anemia on HbA1c 
assays.  
In conclusion, our study suggests 
mechanisms that may underlie the consistent 
association between HK1 genetic variation 
and HbA1c, but also identifies for the first 
time a gene contributing to common pro-
anemic state. At a time where the utility of 
GWAS is debated for disease prediction (50), 
our study highlights GWAS power to identify 
physiological determinants of complex 
conditions such as anemia having serious 
implications for health.  
 
ACKNOWLEDGMENTS 
         We are grateful to all patients and their 
families for participation in the genetic study. 
We thank Marianne Deweirder, Frédéric 
Allegaert and Emmanuel Vaillant for their 
technical assistance and their precious 
management of DNA samples; Stefan Gaget 
and Sophie Gallina for bioinformatics 
support; Sylvie Poulain, Philippe Delfosse 
and Philippe Gallina for the recruitment of 
obesity and T2D families. We are grateful to 
the DIAGRAM+ consortium for providing 
GWAS data on rs7072268, and we 
particularly thank Mark McCarthy and 
Benjamin Voight. Amélie Bonnefond is 
funded by a research fellowship from the HK1 variant, glycated hemoglobin and anemia 
 
  10
Conseil Régional du Nord Pas de Calais 
(France) and the Centre National de la 
Recherche Scientifique (CNRS). This study 
was supported by the French Agence 
Nationale de la Recherche (ANR-08-GENO-
001-01) and the European Union (Integrated 
Project EuroDia LSHM-CT-2006-518153 in 
the Framework Programme 6 [FP6] of the 
European-Community to Philippe Froguel). 
The D.E.S.I.R. study has been supported by 
INSERM, CNAMTS, Lilly, Novartis Pharma 
and Sanofi-Aventis, the Association Diabète 
Risque Vasculaire, the Fédération Française 
de Cardiologie, La Fondation de France, 
ALFEDIAM, ONIVINS, Ardix Medical, 
Bayer Diagnostics, Becton Dickinson, 
Cardionics, Merck Santé, Novo Nordisk, 
Pierre Fabre, Roche and Topcon. The Diab-2-
Néphrogène/Surdiagène study acknowledges 
the participating patients, physicians and the 
staff of the CIC Poitiers, PHRC (Projet 
Hospitalier de Recherche Clinique), and a 
2003-AFD-grant. The NFBC1986 is 
supported by the European Commission; 
contract number QLG1-CT-2000-01643, 
Biocenter, University of Oulu, Finland; and 
the Academy of Finland. We thank Leena 
Peltonen for providing NFBC1986 DNA 
samples. HK1 variant, glycated hemoglobin and anemia 
 
  11
REFERENCES 
1. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, 
Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, 
Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive 
blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 
358:2560-2572, 2008 
2. AmericanDiabetesAssociation: Standards of medical care in diabetes. Diabetes Care 31 Suppl 
1:S12-54, 2008 
3. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the 
glycosylated hemoglobin assay. N Engl J Med 310:341-346, 1984 
4. Nathan DM, Turgeon H, Regan S: Relationship between glycated haemoglobin levels and 
mean glucose levels over time. Diabetologia 50:2239-2244, 2007 
5. Cohen RM, Smith EP: Frequency of HbA1c discordance in estimating blood glucose control. 
Curr Opin Clin Nutr Metab Care 11:512-517, 2008 
6. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner 
CH: Red cell life span heterogeneity in hematologically normal people is sufficient to alter 
HbA1c. Blood 112:4284-4291, 2008 
7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, 
Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, 
Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide 
association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885, 2007 
8. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, 
Almgren P, Andersen G, Ardlie K, Bostrom KB, Bergman RN, Bonnycastle LL, Borch-Johnsen 
K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott 
KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ, 
Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, Jorgensen T, 
Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, 
Lindgren CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, 
Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou 
C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ, Sandbaek A, Shields B, Sjogren M, 
Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, 
Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Illig T, Hveem K, 
Hu FB, Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso I, Hattersley AT, Collins 
FS, Groop L, McCarthy MI, Boehnke M, Altshuler D: Meta-analysis of genome-wide 
association data and large-scale replication identifies additional susceptibility loci for type 2 
diabetes. Nat Genet 40:638-645, 2008 
9. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, 
Delplanque J, Lobbens S, Rocheleau G, Durand E, De Graeve F, Chevre JC, Borch-Johnsen K, 
Hartikainen AL, Ruokonen A, Tichet J, Marre M, Weill J, Heude B, Tauber M, Lemaire K, 
Schuit F, Elliott P, Jorgensen T, Charpentier G, Hadjadj S, Cauchi S, Vaxillaire M, Sladek R, 
Visvikis-Siest S, Balkau B, Levy-Marchal C, Pattou F, Meyre D, Blakemore AI, Jarvelin MR, 
Walley AJ, Hansen T, Dina C, Pedersen O, Froguel P: A variant near MTNR1B is associated 
with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89-94, 2009 
10. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, Cavalcanti-Proenca C, 
Marchand M, Hartikainen AL, Sovio U, De Graeve F, Rung J, Vaxillaire M, Tichet J, Marre M, HK1 variant, glycated hemoglobin and anemia 
 
  12
Balkau B, Weill J, Elliott P, Jarvelin MR, Meyre D, Polychronakos C, Dina C, Sladek R, Froguel 
P: A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. 
Science 320:1085-1088, 2008 
11. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham 
HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, 
Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart 
MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, 
Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, 
Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects 
multiple susceptibility variants. Science 316:1341-1345, 2007 
12. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, 
Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, 
Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, 
Doney AS, McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK 
samples reveals risk loci for type 2 diabetes. Science 316:1336-1341, 2007 
13. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, 
Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, 
Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, 
Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi 
T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, 
Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, 
Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy 
C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, 
Richardson D, Ricke D, Purcell S: Genome-wide association analysis identifies loci for type 2 
diabetes and triglyceride levels. Science 316:1331-1336, 2007 
14. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, 
Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorradottir S, Bjarnason H, 
Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason 
V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RC, Andersen G, Borch-Johnsen K, 
Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, 
Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong 
A, Stefansson K: A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. 
Nat Genet 39:770-775, 2007 
15. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, Silver KD, Timpson NJ, Hansen T, 
Orru M, Grazia Piras M, Bonnycastle LL, Willer CJ, Lyssenko V, Shen H, Kuusisto J, Ebrahim 
S, Sestu N, Duren WL, Spada MC, Stringham HM, Scott LJ, Olla N, Swift AJ, Najjar S, Mitchell 
BD, Lawlor DA, Smith GD, Ben-Shlomo Y, Andersen G, Borch-Johnsen K, Jorgensen T, 
Saramies J, Valle TT, Buchanan TA, Shuldiner AR, Lakatta E, Bergman RN, Uda M, 
Tuomilehto J, Pedersen O, Cao A, Groop L, Mohlke KL, Laakso M, Schlessinger D, Collins FS, 
Altshuler D, Abecasis GR, Boehnke M, Scuteri A, Watanabe RM: Variations in the 
G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 
118:2620-2628, 2008 
16. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, Loos RJ, 
Manning AK, Jackson AU, Aulchenko Y, Potter SC, Erdos MR, Sanna S, Hottenga JJ, Wheeler 
E, Kaakinen M, Lyssenko V, Chen WM, Ahmadi K, Beckmann JS, Bergman RN, Bochud M, 
Bonnycastle LL, Buchanan TA, Cao A, Cervino A, Coin L, Collins FS, Crisponi L, de Geus EJ, HK1 variant, glycated hemoglobin and anemia 
 
  13
Dehghan A, Deloukas P, Doney AS, Elliott P, Freimer N, Gateva V, Herder C, Hofman A, 
Hughes TE, Hunt S, Illig T, Inouye M, Isomaa B, Johnson T, Kong A, Krestyaninova M, 
Kuusisto J, Laakso M, Lim N, Lindblad U, Lindgren CM, McCann OT, Mohlke KL, Morris AD, 
Naitza S, Orru M, Palmer CN, Pouta A, Randall J, Rathmann W, Saramies J, Scheet P, Scott LJ, 
Scuteri A, Sharp S, Sijbrands E, Smit JH, Song K, Steinthorsdottir V, Stringham HM, Tuomi T, 
Tuomilehto J, Uitterlinden AG, Voight BF, Waterworth D, Wichmann HE, Willemsen G, 
Witteman JC, Yuan X, Zhao JH, Zeggini E, Schlessinger D, Sandhu M, Boomsma DI, Uda M, 
Spector TD, Penninx BW, Altshuler D, Vollenweider P, Jarvelin MR, Lakatta E, Waeber G, Fox 
CS, Peltonen L, Groop LC, Mooser V, Cupples LA, Thorsteinsdottir U, Boehnke M, Barroso I, 
Van Duijn C, Dupuis J, Watanabe RM, Stefansson K, McCarthy MI, Wareham NJ, Meigs JB, 
Abecasis GR: Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77-81, 2009 
17. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, Bugliani M, Saxena 
R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto J, Boehnke M, 
Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti P, Watanabe RM, 
Mulder H, Groop L: Common variant in MTNR1B associated with increased risk of type 2 
diabetes and impaired early insulin secretion. Nat Genet 41:82-88, 2009 
18. Sparso T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL, Albrechtsen A, 
Rasmussen SS, Jorgensen T, Borch-Johnsen K, Sandbaek A, Lauritzen T, Madsbad S, Hansen T, 
Pedersen O: The GCKR rs780094 polymorphism is associated with elevated fasting serum 
triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 
diabetes. Diabetologia 51:70-75, 2008 
19. Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, Charpentier G, Tichet J, Fumeron F, 
Marre M, Meyre D, Balkau B, Froguel P: Impact of common type 2 diabetes risk polymorphisms 
in the DESIR prospective study. Diabetes 57:244-254, 2008 
20. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM: Novel 
association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide 
evaluation of 14,618 participants in the Women's Genome Health Study. PLoS Genet 
4:e1000312, 2008 
21. van Wijk R, van Solinge WW: The energy-less red blood cell is lost: erythrocyte enzyme 
abnormalities of glycolysis. Blood 106:4034-4042, 2005 
22. Peters LL, Lane PW, Andersen SG, Gwynn B, Barker JE, Beutler E: Downeast anemia (dea), 
a new mouse model of severe nonspherocytic hemolytic anemia caused by hexokinase (HK(1)) 
deficiency. Blood Cells Mol Dis 27:850-860, 2001 
23. van Wijk R, Rijksen G, Huizinga EG, Nieuwenhuis HK, van Solinge WW: HK Utrecht: 
missense mutation in the active site of human hexokinase associated with hexokinase deficiency 
and severe nonspherocytic hemolytic anemia. Blood 101:345-347, 2003 
24. McMullin MF: The molecular basis of disorders of red cell enzymes. J Clin Pathol 52:241-
244, 1999 
25. Kanno H, Murakami K, Hariyama Y, Ishikawa K, Miwa S, Fujii H: Homozygous intragenic 
deletion of type I hexokinase gene causes lethal hemolytic anemia of the affected fetus. Blood 
100:1930, 2002 
26. Balkau B: [An epidemiologic survey from a network of French Health Examination Centres, 
(D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]. Rev Epidemiol Sante 
Publique 44:373-375, 1996 
27. Steffen R, Potoczna N, Bieri N, Horber FF: Successful multi-intervention treatment of severe 
obesity: a 7-year prospective study with 96% follow-up. Obes Surg 19:3-12, 2009 HK1 variant, glycated hemoglobin and anemia 
 
  14
28. Jarvelin MR, Elliott P, Kleinschmidt I, Martuzzi M, Grundy C, Hartikainen AL, Rantakallio 
P: Ecological and individual predictors of birthweight in a northern Finland birth cohort 1986. 
Paediatr Perinat Epidemiol 11:298-312, 1997 
29. Jaquet D, Collin D, Levy-Marchal C, Czernichow P: Adult height distribution in subjects 
born small for gestational age. Horm Res 62:92-96, 2004 
30. Meyre D, Lecoeur C, Delplanque J, Francke S, Vatin V, Durand E, Weill J, Dina C, Froguel 
P: A genome-wide scan for childhood obesity-associated traits in French families shows 
significant linkage on chromosome 6q22.31-q23.2. Diabetes 53:803-811, 2004 
31. Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Travert F, Abi Khalil 
C, Miot A, Alhenc-Gelas F, Lievre M, Marre M: Prognostic value of the insertion/deletion 
polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-
dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and 
Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique 
(DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. 
Diabetes Care 31:1847-1852, 2008 
32. Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, Roussel AM, Favier A: A 
primary prevention trial using nutritional doses of antioxidant vitamins and minerals in 
cardiovascular diseases and cancers in a general population: the SU.VI.MAX study--design, 
methods, and participant characteristics. SUpplementation en VItamines et Mineraux 
AntioXydants. Control Clin Trials 19:336-351, 1998 
33. Cauchi S, Proenca C, Choquet H, Gaget S, De Graeve F, Marre M, Balkau B, Tichet J, 
Meyre D, Vaxillaire M, Froguel P: Analysis of novel risk loci for type 2 diabetes in a general 
French population: the D.E.S.I.R. study. J Mol Med 86:341-348, 2008 
34. Sparso T, Bonnefond A, Andersson E, Bouatia-Naji N, Holmkvist J, Wegner L, Grarup N, 
Gjesing AP, Banasik K, Cavalcanti-Proenca C, Marchand M, Vaxillaire M, Charpentier G, 
Jarvelin MR, Tichet J, Balkau B, Marre M, Levy-Marcha C, Faerch K, Borch-Johnsen K, 
Jorgensen T, Madsbad S, Poulsen P, Vaag A, Dina C, Hansen T, Pedersen O, Froguel P: The G-
allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia 
and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 
19,605 Europeans. Diabetes, 2009 
35. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 
27:1487-1495, 2004 
36. Wareham NJ, Phillips DI, Byrne CD, Hales CN: The 30 minute insulin incremental response 
in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12:931, 1995 
37. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance 
testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470, 1999 
38. Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of beta-cell 
function: the hyperbolic correction. Diabetes 51 Suppl 1:S212-220, 2002 
39. da-Silva WS, Gomez-Puyou A, de Gomez-Puyou MT, Moreno-Sanchez R, De Felice FG, de 
Meis L, Oliveira MF, Galina A: Mitochondrial bound hexokinase activity as a preventive 
antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane 
potential and reactive oxygen species generation in mitochondria. J Biol Chem 279:39846-
39855, 2004 
40. Pastorino JG, Shulga N, Hoek JB: Mitochondrial binding of hexokinase II inhibits Bax-
induced cytochrome c release and apoptosis. J Biol Chem 277:7610-7618, 2002 HK1 variant, glycated hemoglobin and anemia 
 
  15
41. Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB: Increased hexokinase activity, of either 
ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell 
death. J Biol Chem 277:11392-11400, 2002 
42. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V: Voltage-dependent anion 
channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J Biol 
Chem 284:3946-3955, 2009 
43. Gardiner NJ, Wang Z, Luke C, Gott A, Price SA, Fernyhough P: Expression of hexokinase 
isoforms in the dorsal root ganglion of the adult rat and effect of experimental diabetes. Brain 
Res 1175:143-154, 2007 
44. Singh DK, Winocour P, Farrington K: Erythropoietic stress and anemia in diabetes mellitus. 
Nat Rev Endocrinol 5:204-210, 2009 
45. Hashimoto K, Noguchi S, Morimoto Y, Hamada S, Wasada K, Imai S, Murata Y, Kasayama 
S, Koga M: A1C but not serum glycated albumin is elevated in late pregnancy owing to iron 
deficiency. Diabetes Care 31:1945-1948, 2008 
46. Coban E, Ozdogan M, Timuragaoglu A: Effect of iron deficiency anemia on the levels of 
hemoglobin A1c in nondiabetic patients. Acta Haematol 112:126-128, 2004 
47. Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L: Glycosylated haemoglobin 
(HbA1c) in iron- and vitamin B12 deficiency. J Intern Med 227:133-136, 1990 
48. Bozek K, Relogio A, Kielbasa SM, Heine M, Dame C, Kramer A, Herzel H: Regulation of 
clock-controlled genes in mammals. PLoS ONE 4:e4882, 2009 
49. Ishii H, Tanaka N, Kobayashi M, Kato M, Sakuma Y: Gene structures, biochemical 
characterization and distribution of rat melatonin receptors. J Physiol Sci 59:37-47, 2009 
50. Hirschhorn JN: Genomewide Association Studies -- Illuminating Biologic Pathways. N Engl 
J Med 360:1699-1701, 2009 HK1 variant, glycated hemoglobin and anemia 
 
  16
Figure 1. Cumulative effect of HK1-rs7072268,  MTNR1B-rs10830963,  GCK-rs1799884, 
G6PC2-rs560887 and SLC30A8-rs13266634 on HbA1c in non-diabetic individuals from the 
D.E.S.I.R. study 
A linear regression model was carried out applying an additive model adjusted for age, gender 
and BMI. Data are presented as mean [95% CI]. β coefficient corresponds to the increase in 
HbA1c levels (%) by additional ‘high HbA1c’ alleles. The numbers of individuals per category 
of ‘high HbA1c’ alleles and corresponding percentages are shown below the graph.   
 
 
 HK1 variant, glycated hemoglobin and anemia 
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Table 1. Clinical characteristics and available data on the study populations with successful genotyping for rs7072268  
 
T2D case-control study 
Study 
Populations 
D.E.S.I.R. at 
baseline 
Swiss obese 
adults  NFBC1986 Haguenau 
French 
children from 
obesity 
pedigrees 
French adults 
from obesity 
pedigrees 
French T2D 
case 
French 
controls 
N (M/F)  4,590(2,259 / 
2,331) 
2,363 (511 / 
1852) 
5,287   
(2,628 / 
2,659) 
1,455     
(690 / 765) 
1,411      
(678 / 733) 
3,850     (1,454 
/ 2,396) 
7,447 
(4,752 / 
2,695) 
5,380 
(2,293 / 
3,087) 
Age (years)  47.1 ± 10.0  40.8 ± 11.1  16.0  22.1 ± 3.9  11.4 ± 3.3  46.3 ± 15.2   62.7 ± 10.3  53.0 ± 8.3 
BMI (kg/m²)  24.6 ± 3.7  43.1 ± 7.2  21.3 ± 3.7  22.6 ± 4.1  26.2 ± 7.4  32.5 ± 9.4  30.7 ± 6.2  25.2 ± 5.0 
Fasting glucose 
(mmol/l)  5.3 ± 0.5  5.1 ± 0.6  5.2 ± 0.4  4.8 ± 0.4  4.9 ± 0.5  5.3 ± 0.7  NA  NA 
Fasting insulin 
(pmol/l) 
39.2 
(28.6;55.8) 
110.4 
(75.9;165.6) 
66.2 
(51.2;85.6) 
32.3 
(22.2;43.8) 
69.0 
(42.8;109.7)  55.9(33.3;89.7) NA  NA 
HbA1c (%)  5.43 ± 0.40  5.59 ± 0.48 NA  NA  NA  NA  NA  NA 
Association 
study with 
rs7072268: 
             
HbA1c  ■  ■          
Fasting 
metabolic traits  ■  ■  ■  ■  ■  ■    
Metabolic traits 
during an OGTT       ■  ■  ■    
RBC-related 
parameters  ■  ■  ■       ■*
   
 
T2D, type 2 diabetes; OGTT, oral glucose tolerance test; RBC, red blood cell; NA, not applicable or not available  
Data are presented as mean ± standard deviation or median (interquartile range). 
Available data are presented as ‘■’. 
*RBC-related parameters were only available in T2D patients from the Corbeil-Hospital. 
 HK1 variant, glycated hemoglobin and anemia 
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Table 2. Association of rs7072268 with HbA1c level in non-diabetic individuals from the D.E.S.I.R. study (at baseline and over the 9-year follow-up 
study) and from the Swiss obese adults sample-set 
 
  Mean HbA1c level (%) by genotype*  Additive model adjusted for age, 
gender and BMI 
Additive model adjusted for age, 
gender, BMI and FPG level 
 
N 
T-allele 
frequenc
y 
CC CT TT  Per T allele effect
† 
(%HbA1c) [95% CI]  P  Per T allele effect
† 
(%HbA1c) [95% CI]  P 
D.E.S.I.R.          
At baseline  4,590  0.49  5.40 ± 0.41  5.43 ± 0.39  5.45 ± 0.39  0.023 [0.016;0.031]  1.76 × 10
-3  0.026 [0.018;0.033]  4.03 × 10
-4 
Swiss obese 
adults  2,363  0.54  5.56 ± 0.45  5.58 ± 0.48  5.64 ± 0.49  0.046 [0.032;0.060]  9.46 × 10
-4  0.035 [0.026;0.044]  1.13 × 10
-4 
Meta-analysis  6,953  -  -  -  -  0.028 [0.016;0.041]  1.53 × 10
-5  0.029 [0.018;0.040]  2.22 × 10
-7 
D.E.S.I.R. over the 
9-year follow-up 
study
‡ 
15,073  0.49  - - -  0.022  [0.016;0.029]  3.93 × 10
-4  0.023 [0.017;0.029]  1.20 × 10
-4 
 
Association between rs7072268 and HbA1c was assessed applying an additive model adjusted for age, gender and BMI or adjusted for age, gender, BMI and 
fasting plasma glucose (FPG).  
*Data are presented as mean ± standard deviation. 
†Per T-allele effect size means the regression coefficient β. 
‡P values and regression coefficients β are calculated from mixed models described in the statistical analysis section. HK1 variant, glycated hemoglobin and anemia 
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Table 3. Associations between rs7072268 and glucose homeostasis-related traits in non-diabetic individuals from several European cohorts 
      Mean data level by genotype*   
 T-allele 
frequenc
y 
N  Glucose homeostasis-
related traits  CC CT TT  P 
Fasting glucose(mmol/l) 5.29 ± 0.53  5.27 ± 0.52  5.28 ± 0.54  0.66 
Fasting insulin
† (pmol/l)  39.22(28.63-56.82)  39.15(28.54-55.61) 39.58(28.82-55.78) 0.78 
HOMA-B
†  67.65(48.06-94.05)  67.67(49.19-95.41) 69.51(49.52-93.61)  0.79 
D.E.S.I.R. 0.49  4,590 
HOMA-IR
†   9.15(6.43-13.66)  9.17(6.48-13.23) 9.19(6.44-13.72)  0.74 
Fasting glucose(mmol/l) 5.14 ± 0.63  5.11 ± 0.58  5.16 ± 0.57  0.44 
Fasting insulin
† (pmol/l)  103.5(69-158.7)  110.4(75.9-165.6) 110.4(75.9-172.2) 0.08 
HOMA-B
†  200.0(132.5-306.1)  216.0(137.7-329.2) 200.0(137.5-314.3)  0.24 
Swiss Obese 
adults  0.54 2,101 
HOMA-IR
†   24.2(15.5-36.2)  24.9(16.9-36.7) 25.5(16.3-38.3)  0.10 
Fasting glucose(mmol/l) 5.15 ± 0.44  5.15 ± 0.43  5.14 ± 0.41  0.81 
Fasting insulin
† (pmol/l)  66.24(51.06-87.63)  66.24(51.06-84.67) 67.62(51.06-86.25) 0.53 
HOMA-B
†  118.67(90.00-156.67)  117.89(92.00-156.21) 120.00(90.00-156.67)  0.75 
NFBC1986 0.40  5,287 
HOMA-IR
†   15.03(11.50-20.16)  15.12(11.43-19.77) 15.35(11.57-19.73) 0.52 
Fasting glucose(mmol/l) 4.76 ± 0.35  4.80 ± 0.38   4.79 ± 0.39  0.29 
Fasting insulin
† (pmol/l)  33.01(22.96-44.49) 33.01(22.96-44.49) 30.49 (21.53-43.59)  0.82 
HOMA-B
†  78.09(50.61-112.93)  75.09(51.23-107.05) 72.82(50.06-104.93) 0.74 
Haguenau 0.52  1,455 
HOMA-IR
†    7.08(4.79-9.48) 6.97(4.89-9.55) 6.57(4.48-9.34)  0.72 
Fasting glucose(mmol/l) 4.89 ± 0.47  4.93 ± 0.48  4.86 ± 0.51  0.30 
Fasting insulin
† (pmol/l)  68.31(42.78-107.30)  68.31(42.44-107.30) 70.38(44.85-112.47) 0.89 
HOMA-B
†  151.76(99.44-225.38)  145.33(94.87-229.43) 152.73(94.44-253.33)  0.66 
French children 
from obesity 
pedigrees 
0.49 1,411 
HOMA-IR
†   15.13(8.89-23.09)  14.95(8.98-24.04) 14.72(9.44-25.07) 0.98 
Fasting glucose(mmol/l) 5.33 ± 0.68  5.34 ± 0.69  5.36 ± 0.67  0.76 
Fasting insulin
† (pmol/l)  54.17(33.12-84.70)  55.20(33.12-89.01) 58.65(34.50-93.84) 0.25 
HOMA-B
†  87.55(56.32-141.14)  93.52(57.38-142.71) 96.36(59.64-151.54) 0.45 
French adults 
from obesity 
pedigrees 
0.51 3,850 
HOMA-IR
†   12.74(7.42-20.62)  13.26(7.43-21.42) 14.03(7.82-23.30) 0.23 
Fasting  glucose(mmol/l) - - -  0.93 
Fasting insulin
†  (pmol/l)  - - -  0.79 
HOMA-B
†   - - -  0.90 
Overall Meta-
analysis  - 18,694 
HOMA-IR
†    - - -  0.81 
Associations between rs7072268 and glucose homeostasis-related traits were assessed applying an additive model adjusted for age, gender and BMI, except for 
the NFBC1986 (an adjustment for gender and BMI was only performed as they were all 16 years old).    
HOMA-B, homeostasis model of pancreatic beta cell function; HOMA-IR, homeostasis model of insulin resistance 
*Data are presented as mean ± standard deviation and for logarithmically transformed data as median (interquartile range).  
†Values of fasting serum insulin, HOMA-B and HOMA-IR were logarithmically transformed before statistical analysis.  HK1 variant, glycated hemoglobin and anemia 
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Table 4. Associations between rs7072268 and quantitative metabolic traits during an OGTT in non-diabetic French individuals from the Haguenau 
study and obesity pedigrees 
       Mean data level by genotype*   
  N  T-allele 
frequency  Quantitative metabolic traits during an OGTT  CC  CT  TT  P 
      Plasma glucose  30min post OGTT  7.24 ± 1.42  7.20 ± 1.52  7.29 ± 1.49  0.85 
      (mmol/l)  120min post OGTT  5.47 ± 1.13  5.39 ± 1.18  5.39 ± 1.16  0.22 
French     Serum  insulin
†  30min post OGTT  498(283-732)  448(275-698)  461(274-763)  0.57 
Children  1,055  0.49  (pmol/l)  120min post OGTT 206(107-411)  193(99-401)  213(100-451)  0.72 
from obesity      Insulinogenic Index
†   58.7(34.5-84.7)  54.4(31.6-82.4) 54.3(33.4-89.9)  0.96 
pedigrees     ISI
†   32.5(21.3-55.4) 37.0(23.4-58.1) 33.8(21.3-57.2)  0.43 
     DI
†   10,025(5,539-18,125) 10,827(6,013-18,391)  9,012(5,345-16,832) 0.83 
      Plasma glucose  30min post OGTT  8.22 ± 1.67  8.40 ± 1.90  8.32 ± 1.85  0.70 
      (mmol/l)  120min post OGTT  5.68 ± 1.95  5.72 ± 1.92  5.78 ± 1.97  0.43 
French 2,294 0.51  Serum  insulin
†  30min post OGTT  293(167-490)  305(182-481)  295(165-485)  0.97 
Children      (pmol/l)  120min post OGTT 168(79-366)  182(83-370)  190(91-364)  0.27 
from obesity      Insulinogenic Index
†   30.4(16.5-50.5)  30.4(16.5-50.0) 28.5(16.1-49.6)  0.56 
pedigrees     ISI
†   106.6(60.2-192.6)  102.4(62.3-170.0) 107.0(57.5-174.8)  0.46 
     DI
†   13,046(6,496-26,909)  12,806(6,130-25,563) 13,005(5,841-24,931) 0.41 
      Plasma glucose  30min post OGTT  7.51 ± 1.42  7.61 ± 1.46  7.49 ± 1.40  0.60 
      (mmol/l)  120min post OGTT  5.40 ± 1.22  5.30 ± 1.14  5.27 ± 1.18  0.17 
Haguenau 1,440  0.52  Serum  insulin
†  30min post OGTT  294(185-445)  287 (187-420)  287(181-434)  0.82 
      (pmol/l)  120min post OGTT  165(93-266) 172(108-273)  165(101-266)  0.99 
     Insulinogenic  Index
†   34.9(20.6-53.6)  33.1(21.6-50.8) 34.8(21.6-50.9)  0.87 
      Plasma glucose  30min post OGTT  -  -  -  0.99 
      (mmol/l)  120min post OGTT  -  -  -  - 
Overall 4789  -  Serum  insulin
†  30min post OGTT  -  -  -  0.99 
Meta-analysis      (pmol/l)  120min post OGTT  -  -  -  0.24 
     Insulinogenic  Index
†   -  -  0.84  0.71 
     ISI
†   -  -  0.92  0.83 
     DI
†   -  -  -  0.42 
Associations between rs7072268 and quantitative metabolic traits during an OGTT were assessed applying an additive model adjusted for age, gender and BMI.  
OGTT, oral glucose tolerance test; ISI, Insulin Sensitivity Index; DI, disposition index 
*Data are presented as mean ± standard deviation and for logarithmically transformed data as median (interquartile range). 
†Values of serum insulin, ISI, DI and Insulinogenic Index were logarithmically transformed before statistical analysis. HK1 variant, glycated hemoglobin and anemia 
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‡Meta-analyses of both ISI and DI included association data of the participants from obesity French pedigrees only.  
 
Table 5. Associations between rs7072268 and RBC-related parameters in non-diabetic individuals from D.E.S.I.R. (at baseline and over the 9-year 
follow-up), the Swiss obese adults and the NFBC1986; and in diabetic French participants from the Corbeil T2D study  
    Mean data level by genotype*     
 T-allele 
frequency  N  RBC-related parameters  CC  CT  TT  Per T allele effect
† [95% CI]  P 
RBC count (×10
12/l)  4.82 ± 0.41  4.79 ± 0.41  4.78 ± 0.41  -0.018 [-0.025;-0.011]  8.01 × 10
-3 
Hematocrit (%)  43.66 ± 3.61  43.50 ± 3.61  43.28 ± 3.67  -0.18 [-0.24;-0.12]  2.11 × 10
-3 
Hemoglobin (g/dl)  14.41 ± 1.26  14.36 ± 1.24  14.30 ± 1.28  -0.054 [-0.074;-0.035]  5.20 × 10
-3 
MCH (pg/cell)  29.95 ± 1.54  30.00 ± 1.57  29.94 ± 1.64  -  0.98 
MCV (×10
-15 liters/cell)  90.73 ± 4.18  90.88 ± 4.33  90.65 ± 4.34  -  0.68 
D.E.S.I.R.At 
baseline  0.49 4,576 
MCHC (%)  33.01 ± 0.96  33.01 ± 1.06  33.03 ± 0.97  -  0.57 
RBC count (×10
12/l)  4.81 ± 0.37  4.84 ± 0.39  4.84 ± 0.38  -  0.31 
Hematocrit (%)  43.19 ± 3.32  43.19 ± 3.36  42.93 ± 3.10  -0.17 [-0.27;-0.070] 0.087 
Hemoglobin (g/dl)  14.35 ± 1.19  14.28 ± 1.26  14.22 ± 1.24  -0.081 [-0.115;-0.046] 0.019 
MCH (pg/cell)  29.86 ± 1.77  29.68 ± 1.85  29.46 ± 2.22  -0.21 [-0.28;-0.14]  2.16 × 10
-3 
MCV (×10
-15 liters/cell)  90.05 ± 4.77  89.55 ± 4.56  88.92 ± 5.39  -0.56 [-0.72;-0.38]  1.29 × 10
-3 
Swiss 
Obese 
adults  
0.54 1,687 
MCHC (%)  33.16 ± 1.18  33.15 ± 1.12  33.11 ± 1.18  -  0.29 
RBC count (×10
12/l)  4.71 ± 0.40  4.70 ± 0.42  4.70 ± 0.42  -  0.66 
Hematocrit (%)  40.67 ± 3.35  40.49 ± 3.53  40.49 ± 3.55  -0.086 [-0.137;-0.035] 0.094 
Hemoglobin (g/dl)  13.77 ± 1.20  13.71 ± 1.23  13.20 ± 1.28  -0.030 [-0.047;-0.012] 0.087 
MCH (pg/cell)  29.40 ± 1.77  29.31 ± 1.87  29.30 ± 1.85  -  0.12 
MCV (×10
-15 liters/cell)  86.42 ± 4.05  86.28 ± 4.21  86.32 ± 4.45  -  0.45 
NFBC1986 0.40 5,229 
MCHC (%)  33.89 ± 0.95  33.84 ± 0.98  33.86 ± 0.97  -  0.24 
RBC count (×10
12/l) -  -  -  -0.0068  [-0.015;0.0015]  0.11 
Hematocrit (%)  -  -  -  -0.13 [-0.20;-0.06]   2.26 × 10
-4 
Hemoglobin (g/dl)  -  -  -  -0.044 [-0.071;-0.017]  1.43 × 10
-3 
MCH (pg/cell)  -  -  -  NA
‡ NA
‡ 
MCV (×10
-15 liters/cell)  -  -  -  NA
‡ NA
‡ 
Meta-
analysis    11,492 
MCHC (%)  -  -  -  0.0005 [-0.036;0.037]  0.42 
Hemoglobin (g/dl)  14.30 ± 1.32  14.25 ± 1.33  14.07 ± 1.35  -0.13 [-0.16;-0.09]  7.66 × 10
-4  Corbeil T2D 
study 
0.52 1,924 
MCV (×10
-15 liters/cell)  90.26 ± 6.20  90.07 ± 5.49  89.63 ± 6.10  -0.33 [-0.51;-0.15] 0.070 
Hemoglobin (g/dl)  -  -  -  -0.054 [-0.076;-0.031]  3.74 × 10
-6  Overall 
Meta-
analysis 
- 13,416 
MCV (×10
-15 liters/cell)  -  -  -  NA
‡ NA
‡ 
RBC count (×10
12/l)  -  -  -  -0,020 [-0.027;-0.014]  9.63 × 10
-4 
Hematocrit (%)  -  -  -  -0.17 [-0.22;-0.12]  3.73 × 10
-4 
Hemoglobin (g/dl)  -  -  -  -0.055 [-0.071;-0.038]  1.04 × 10
-3 
MCH (pg/cell)  -  -  -  -  0.43 
MCV (×10
-15 liters/cell)  -  -  -  -  0.72 
D.E.S.I.R. 
over the 9-
year follow-
up study
§ 
0.49 15,119 
MCHC (%)  -  -  -  -  0.55 HK1 variant, glycated hemoglobin and anemia 
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Associations between rs7072268 and RBC-related parameters were assessed applying an additive model adjusted for age, gender and BMI. 
RBC, red blood cell; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; NA, not 
applicable; T2D, type 2 diabetes.  
*Data are presented as mean ± standard deviation. 
†Per T-allele effect size means the regression coefficient β. We only displayed the T-allele effect when P was lower than 0.10. 
‡The P values for heterogeneity in effects on both MCH and MCV indices were lower than 0.05. We thus considered these two traits as not applicable for overall 
meta-analyses.  
§P values and regression coefficients β are calculated from mixed additive models. 
 
 Table 6. French type 2 diabetes case control analyses according to SNP rs7072268 
     n [frequency] in each genotypic group     
  T-allele 
frequency  N  CC  CT  TT  OR* [95% CI]  P 
T2D French participants  0.51  7,447  1,784  [0.24]  3,708 [0.50]  1,955 [0.26]  Ref.  - 
French controls  0.50  5,380  1,327 [0.25]  2,715 [0.50]  1,338 [0.25]  1.069 
[1.001;1.142]  0.045 
Type 2 diabetes (T2D) was defined according to 1997 American Diabetes Association criteria (2).  
*OR from additive logistic regression models adjusted for age, sex and BMI 
 
Table 7. Association of HbA1c, fasting glucose, hemoglobin, hematocrit and RBC count with candidate SNPs in non-diabetic participants from the 
D.E.S.I.R. study at baseline 
HK1 rs7072268-T (frequency: 
0.49; N=4,590) 
MTNR1B rs10830963-G 
(frequency: 0.28; 
N=4,597) 
GCK rs1799884-A 
(frequency: 0.27; 
N=4,406) 
G6PC2 rs560887-
A(frequency: 0.30; 
N=4,339) 
SLC30A8 rs13266634-T 
(frequency: 0.30; N=4,488) 
 
β [95% CI]  P  β [95% CI]  P  β [95% CI]  P  β [95% CI]  P  β [95% CI]  P 
HbA1c (%)  0.023 [0.016;0.031]  1.76 × 10
-3 
0.031 
[0.023;0.039
] 
2.25 × 10
-4 
0.038 
[0.028;0.048
] 
1.32 × 10
-4  -0.040 [-
0.049;-0.032] 
2.31 × 
10
-6  -0.016 [-0.024;-0.007]  0.063 
Fasting glucose 
(mmol/l) 
-0.004 [-
0.014;0.006]  0.66 
0.093 
[0.082;0.104
] 
1.32 × 10
-
16 
0.054 
[0.041;0.067
] 
4.63 × 10
-5  -0.077 [-
0.089;-0.066] 
4.72 × 
10
-12  -0.039 [-0.050;-0.028]  4.54 × 10
-4 
Hemoglobin (g/dl)  -0.054 [-0.074;-
0.035]  5.20 × 10
-3 
-0.055 [-
0.076;-
0.033] 
0.011  0.023 [-
0.002;0.049]  0.35  0.010[-
0.012;0.031]  0.65 0.004  [-0.017;0.026] 0.85 
Hematocrit (%)  -0.18[-0.24;-0.12]  2.11 × 10
-3  -0.19[-0.25;-
0.12]  4.13 × 10
-3  0.020[-
0.058;0.097]  0.80  0.066 
[0.0009;0.13]  0.31 0.008  [-0.057;0.073] 0.91 
RBC count (×10
12/l)  -0.018 [-0.025;-
0.011]  8.01 × 10
-3 
-0.017 [-
0.025;-
0.0097] 
0.022  0.001[-
0.008;0.010]  0.88  0.0005 [-
0.007;0.008]  0.94 0.002  [-0.005;0.010] 0.78 
Associations between SNPs and quantitative traits were assessed applying an additive model adjusted for age, gender and BMI. 
RBC, red blood cell 